12S170: Abstracts: Vasculitis – ANCA-Associated I (0853–0858)

Presenting Author(s)

• MD

  Martin Dutertre, MD (he/him/his)

  AP-HP
  Paris, France

  Disclosure information not submitted.
• 

  David Jayne, MD

  University of Cambridge
  Cambridge, United Kingdom

  Disclosure(s): AstraZeneca: Consultant (Ongoing); Aurinia: Officer or Board Member (Ongoing); Boehringer Ingelheim: Consultant (Ongoing); Chinook: Consultant (Ongoing); CSL Vifor: Consultant (Ongoing); Roche: Consultant (Ongoing)
• BM

  Berengere Molina, MD

  Cochin Hospital
  Paris, France

  Disclosure information not submitted.
• 

  Sebastian Sattui, MD, MS (he/him/his)

  University of Pittsburgh
  Pittsburgh, PA, United States

  Disclosure(s): No relevant disclosure to display
• BT

  Benjamin Terrier, MD, PhD

  Cochin Hospital
  Paris, France

  Disclosure information not submitted.
• ZW

  Zachary Wallace, MD, MSc

  Massachusetts General Hospital
  Newton, MA, United States

  Disclosure(s): BioCryst: Consultant (Ongoing); Bristol-Myers Squibb(BMS): Grant/Research Support (Terminated, April 1, 2023); Horizon: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing); MedPace: Consultant (Ongoing); Novartis: Advisor or Review Panel Member (Terminated, February 1, 2023); PPD: Consultant (Ongoing); Sanofi: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); Shionogi: Advisor or Review Panel Member (Terminated, May 1, 2022); Visterra: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Zenas: Advisor or Review Panel Member (Terminated, January 1, 2023), Consultant (Terminated, January 1, 2023)

Abstract oral session.

Non-CME

Presentations:

• 4:00 PM – 4:10 PM PT

  Early Experience with Avacopan for ANCA-Associated Vasculitis in a Large Integrated Healthcare System
  

  Presenting Author: Zachary Wallace, MD, MSc – Massachusetts General Hospital
• 4:10 PM – 4:15 PM PT

  Q&A
  
• 4:15 PM – 4:25 PM PT

  Long-term Efficacy of Remission-induction Regimens for Eosinophilic Granulomatosis with Polyangiitis
  

  Presenting Author: Martin Dutertre, MD (he/him/his) – AP-HP
• 4:25 PM – 4:30 PM PT

  Q&A
  
• 4:30 PM – 4:40 PM PT

  Real-world Experience with Avacopan in ANCA Vasculitis: A Multi-center Retrospective Cohort Analysis
  

  Presenting Author: Sebastian Sattui, MD, MS (he/him/his) – University of Pittsburgh
• 4:40 PM – 4:45 PM PT

  Q&A
  
• 4:45 PM – 4:55 PM PT

  Dupilumab for Relapsing or Refractory Eosinophilic Granulomatosis with Polyangiitis: A European Retrospective Study
  

  Presenting Author: Berengere Molina, MD – Cochin Hospital
• 4:55 PM – 5:00 PM PT

  Q&A
  
• 5:00 PM – 5:10 PM PT

  Change in Albuminuria in Patients with ANCA-Associated Vasculitis Treated with Avacopan
  

  Presenting Author: David R W Jayne, MD – University of Cambridge
• 5:10 PM – 5:15 PM PT

  Q&A
  
• 5:15 PM – 5:25 PM PT

  Randomized, Controlled, Double-Blind Trial on the Impact of Rosuvastatin on Sublinical Markers of Atherosclerosis in Patients with ANCA-Associated Vasculitis
  

  Presenting Author: Benjamin Terrier, MD, PhD – Cochin Hospital
• 5:25 PM – 5:30 PM PT

  Q&A